Results 201 to 210 of about 616,613 (359)

ProTides for Antiviral Activity Beyond Liver Cells

Chemistry – A European Journal, EarlyView.
A strategy for obtaining prodrugs of antiviral nucleotides with broad tissue activity is presented that relies on cycloalkyl or cycloalkylalkyl esters, improving uptake and esterase cleavage, and producing nanomolar inhibitors in kidney, colon, and lung cells.
Felix Goebel, Adrian Humboldt, Heeyoung Kim, Carl J. M. Schölzel, Ralf Bartenschlager, Clemens Richert   +5 more
wiley   +1 more source

Noninvasive tests for nonalcoholic fatty liver disease in a multi‐ethnic population: The HELIUS study

Hepatology Communications, EarlyView., 2022
Abstract Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence and severity globally, prompting noninvasive testing, yet limited data exist on noninvasive liver tests (NITs) including transient elastography (TE) in ethnically diverse populations.
Anne‐Marieke van Dijk, Yasaman Vali, Anne Linde Mak, Henrike Galenkamp, Max Nieuwdorp, Bert‐Jan van den Born, Adriaan Georgius Holleboom   +6 more
wiley   +1 more source

On the Future of Therapeutic Vaccination in Chronic Hepatitis B [PDF]

, 2019
Julio César Aguilar Rubido
openalex   +1 more source

Advancing Clinical Research

Advanced Science, EarlyView.
wiley   +1 more source

Advancing Maternal Health with Long‐Acting Therapeutics: Priorities, Efficacy and Safety Considerations, and Emerging Technologies

Clinical Pharmacology &Therapeutics, EarlyView.
Maternal health remains a critical global concern, particularly in underserved populations and in low‐ and middle‐income countries where access to safe and effective therapeutics is limited. Despite the use of medications by most women during pregnancy, the exclusion of pregnant and lactating women from clinical trials has resulted in significant data ...
Rachel K. Scott, Sharon Nachman, Ethel D. Weld, Rachel Daley, Shakir Atoyebi, Robert Bies, Catriona Waitt, Adeniyi Olagunju   +7 more
wiley   +1 more source

Baseline HCV‐RNA levels in genotype 1 chronic hepatitis C patients: The role of different cut‐off points [PDF]

, 2016
Marı́a Buti, Juan José Sánchez‐Ruano, Rosa M. Morillas, Rafael Esteban   +3 more
openalex   +1 more source

Clinical Pharmacology Quality Assurance Program for Global HIV and Co‐Infection Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics.
Robin DiFrancesco, Troy D. Wood, Raymond Cha, Jill S. Hochreiter, Susan L. Rosenkranz, Mona Farhad, Kyle R. Whitson, Connor E. Gould, Lauren E. Hill, Linda L. Hale, Philip H. Lindhorst, Diala Ghazal, Charlene R. Taylor, Madiha Quraishi, Suzanne M. Siminski, Yoninah Cramer, Heather L. Sprenger, Gene D. Morse   +17 more
wiley   +1 more source

Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B

, 2003
Ye-gui Jiang
openalex   +2 more sources

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

The impact of chronic hepatitis B and chronic hepatitis C on sexual function: a systematic review and meta-analysis. [PDF]

Reprod Health
Zhang JZ, Zheng J, Zhang YP, Liu CH, Song XN, Shen YL, Tang H, Li H.   +7 more
europepmc   +1 more source